People's daily, Beijing, August 10 (reporter Sun Hongli) the National Health Commission and the State Administration of traditional Chinese Medicine issued the notice on the inclusion of azvudine tablets in the diagnosis and treatment plan of novel coronavirus pneumonia (hereinafter referred to as the notice) on the 9th, which pointed out that according to the approval opinions of the State Food and Drug Administration on the application for registration of azvudine tablets to increase the indications for treatment of novel coronavirus pneumonia, In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnosis and treatment scheme for novel coronavirus pneumonia (Ninth Edition) after research. According to the notice, azivudine tablets are used to treat adult patients with common novel coronavirus pneumonia (covid-19). The whole tablets are taken on an empty stomach, 5mg each time, once a day, and the course of treatment is not more than 14 days. It is not recommended to use it during pregnancy and lactation. It should be used with caution in patients with moderate or severe liver and kidney function damage. The notice emphasizes that before using the drug, you should read the instructions for azvudine tablets approved by the State Food and Drug Administration in detail, and use the drug correctly according to the indications, usage and dosage specified in the instructions. Patients should take medicine under the guidance of doctors. Before prescribing the drug, the doctor should be familiar with the contraindications, adverse reactions, drug interactions, etc., and ask the patient about the drug allergy history in detail to avoid the use of the drug by patients with contraindications. All localities should do a good job in monitoring and reporting adverse drug reactions in strict accordance with the requirements of the administrative measures for reporting and monitoring adverse drug reactions to ensure drug safety. According to the data, on July 25, the State Food and drug administration carried out emergency review and approval according to the relevant provisions of the drug administration law and the special drug approval procedures, and conditionally approved the application of azvudine tablets of Henan Zhenzhen Biotechnology Co., Ltd. for increasing the indications for the treatment of novel coronavirus pneumonia. This product is an oral small molecule novel coronavirus pneumonia treatment drug independently developed by China. On July 20, 2021, the State Food and drug administration has conditionally approved the combination of this product and other reverse transcriptase inhibitors to treat adult HIV-1 infected patients with high viral load. This is an additional indication with conditional approval for the treatment of adult patients with common novel coronavirus pneumonia (covid-19). Patients should take medicine strictly according to the instructions under the guidance of doctors. (outlook new era)